<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449706</url>
  </required_header>
  <id_info>
    <org_study_id>ACS</org_study_id>
    <nct_id>NCT03449706</nct_id>
  </id_info>
  <brief_title>Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection</brief_title>
  <acronym>ACS</acronym>
  <official_title>Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective longitudinal study we aim to assess how immunologic and viral aspects of&#xD;
      the human immunodeficiency virus (HIV) viral reservoir, established during early HIV&#xD;
      infection and responsible for viral rebound at treatment interruption, evolve in individuals&#xD;
      who start combination anti-retroviral therapy (cART) during acute seroconversion.&#xD;
&#xD;
      Recently infected patients will be selected based on Fiebig staging for an in depth sampling&#xD;
      protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode&#xD;
      resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be&#xD;
      performed. Immunological, virological and genome expression analysis will be performed on the&#xD;
      gathered samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of virological and immunological parameters of the HIV reservoir in recently infected HIV positive patients that started treatment during acute seroconversion.</measure>
    <time_frame>10 years</time_frame>
    <description>Virological, immunological and gene expression analysis on blood and tissue from in depth sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of microbiome in recently infected HIV positive patients that started treatment during acute seroconversion.</measure>
    <time_frame>10 years</time_frame>
    <description>Microbiome analysis on stoolsamples.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV</condition>
  <condition>Seroconversion, HIV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early combination anti-retroviral treatment</intervention_name>
    <description>Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Colon biopsy&#xD;
&#xD;
        -  Lymphnode biopsy&#xD;
&#xD;
        -  Cerebrospinal fluids&#xD;
&#xD;
        -  Whole blood&#xD;
&#xD;
        -  Leucapheresis apherate&#xD;
&#xD;
        -  Stool&#xD;
&#xD;
        -  Urine&#xD;
&#xD;
        -  Sperm&#xD;
&#xD;
        -  Cervicovaginal liquid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll a minimum of 30 patients and a maximum of 50 participants (Fiebig stages I -&#xD;
        VI) in the study to establish a cohort of early treated patients. We aim at including at&#xD;
        least 15 people with an incomplete Western Blot (Fiebig I-&gt;IV) and as a control we will&#xD;
        also include patients with complete Western Blot and history of a semi-recent infection&#xD;
        (Fiebig V-VI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented recent HIV-1 infection, early diagnosis: clinical symptoms of acute&#xD;
             seroconversion and incomplete Western Blot OR negative screening test within the past&#xD;
             6 months and incomplete Western Blot OR risk contact within the 3 months and&#xD;
             presumable primo-infection with or without clinical symptoms and incomplete Western&#xD;
             Blot&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  Ability to attend the complete schedule of assessments and patient visits for patients&#xD;
             participating in option A schedule (described below), or ability to attend a partial&#xD;
             schedule of assessments and patient visits for patients participating in option B&#xD;
             (described below).&#xD;
&#xD;
          -  Ability and willingness to have blood and tissue samples collected and stored&#xD;
             indefinitely and used for various research purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current history of opportunistic infection (AIDS defining events as&#xD;
             defined in category C of the CDC clinical classification), consisting of chronic HIV-1&#xD;
             infection.&#xD;
&#xD;
          -  Evidence of active HBV infection (Hepatitis B surface antigen positive or HBV viral&#xD;
             load positive in the past and no evidence of subsequent seroconversion (=HBV antigen&#xD;
             or viral load negative and positive HBV surface antibody).&#xD;
&#xD;
          -  Evidence of active HCV infection: HCV antibody positive result within 60 days prior to&#xD;
             study entry with positive HCV viral load or, if the HCV antibody result is negative, a&#xD;
             positive HCV RNA result within 60 days prior to study entry.&#xD;
&#xD;
          -  Current or known history of cardiomyopathy or significant ischemic or cerebrovascular&#xD;
             disease.&#xD;
&#xD;
          -  Current history of cancer.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Any conditions, including psychiatric and psychological disorders, which will in the&#xD;
             opinion of the investigator interfere with the trial conduct or safety of the&#xD;
             participant.&#xD;
&#xD;
          -  Previous participation in a trial evaluating an immune modulating agent&#xD;
&#xD;
          -  Abnormal laboratory tests results at screening: confirmed Hemoglobin &lt;11g/dl for women&#xD;
             and &lt;12 g:dl for men/ confirmed platelet count &lt; 100000/l / confirmed neutrophil count&#xD;
             &lt;1000/Î¼l/ confirmed AST and/or ALT &gt; 3xULN&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Acute or serious illness, in the opinion of the site investigator, requiring systemic&#xD;
             treatment and/or hospitalization within 60 days prior to entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linos Vandekerckhove, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linos Vandekerckhove, Prof. Dr.</last_name>
    <phone>+3293323398</phone>
    <email>linos.vandekerckhove@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linos Vandekerckhove, Prof. Dr.</last_name>
      <phone>+3293323398</phone>
      <email>linos.vandekerchove@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Linos Vandekerckhove, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Algemene Inwendige Ziekten</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>Reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03449706/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03449706/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

